UBS raised the firm’s price target on Boston Scientific (BSX) to $140 from $135 and keeps a Buy rating on the shares following the Q3 report. The company’s momentum is not slowing down following another quarter of organic sales and earnings growth above consensus, the analyst tells investors in a research note. UBS believes Boston Scientific continues to benefit from the “most positive product cycle in all of large-cap MedTech.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $125 from $124 at Wells Fargo
- Boston Scientific’s Strong Performance and Promising Outlook Justifies Buy Rating
- Boston Scientific Reports Strong Q3 2025 Results
- Boston Scientific price target raised to $124 from $120 at Goldman Sachs
- Boston Scientific’s Strong Q3 Performance and WATCHMAN Growth Justify Buy Rating